Major Review Finds Cancer Is Linked to Reduced Heart Rate Variability

Image:

The human heart does not beat with perfect regularity. Tiny changes in the spacing between beats, measured in milliseconds, reflect the ongoing balance between the sympathetic nervous system, which speeds the heart under stress, and the parasympathetic vagus nerve, which slows it during rest. This beat-to-beat variation is known as heart rate variability, or HRV, and it has long been used as a noninvasive marker of autonomic nervous system function. A systematic review and meta-analysis published in Supportive Care in Cancer now indicates that people with cancer, across several tumor types, tend to have consistently lower short-term HRV than people without cancer. The authors, however, stress that the result is strong in direction but still limited by important scientific caveats.

Led by Hsiu-Hua Shih and Tsai-Wei Huang of Taipei Medical University, the research team searched five major biomedical databases—PubMed, MEDLINE, CINAHL, Embase, and the Cochrane Library—and identified studies covering nine cancer categories. In total, 28 studies involving 3,232 participants met the inclusion criteria. Eligible studies included adults with physician-confirmed cancer and HRV measured by electrocardiography or by photoplethysmography, the optical sensing method used in many smartwatches and fitness bands. This broad evidence base is important because oncology HRV research has often been limited to small, isolated studies, making it hard to estimate the size of the difference between cancer patients and healthy controls.

The analysis depended on one major methodological choice. Time-domain HRV measures such as SDNN, which reflects the standard deviation of normal-to-normal heartbeat intervals, change depending on how long the recording lasts. A 24-hour recording naturally produces larger values than a five-minute resting sample, so combining them would mix measurement effects with biology. For that reason, the main quantitative pool—labeled Part A—was limited to short-term resting recordings of five to ten minutes from studies using age-matched non-cancer controls. Only five studies qualified for this main analysis. Longer recordings of 12 to 30 hours were reported separately, while the remaining studies were summarized narratively or examined for changes over time. The authors used a DerSimonian–Laird random-effects model, rated certainty with the GRADE framework, and preregistered the protocol as PROSPERO CRD42026130103.

The pooled findings pointed in the same direction across the main measures. Compared with controls, cancer patients had lower SDNN by 14.05 milliseconds on average, with a 95 percent confidence interval of 9.90 to 18.20 milliseconds. RMSSD, a measure closely tied to vagal parasympathetic activity, was lower by 16.76 milliseconds. The percentage of successive intervals differing by more than 50 milliseconds, known as pNN50, was reduced by 6.05 percentage points. All three results were statistically significant with p values below 0.001. Study heterogeneity was modest, with I-squared values between 22.1 and 33.7 percent, which is unusually low for a clinical meta-analysis. Sensitivity checks in which studies were removed one at a time showed that the overall conclusions remained stable.

Not every HRV indicator behaved the same way. High-frequency power, another measure associated with parasympathetic activity, did not show a statistically significant difference between cancer patients and controls, with a p value of 0.118. That split between the time-domain measures and the frequency-domain result highlights an important point: HRV is not a single value, but a set of related indices that capture different aspects of autonomic control and are influenced by different technical and physiological factors. Short-recording time-domain measures are especially sensitive to overall beat-to-beat variability, while spectral measures are more dependent on breathing patterns, recording conditions, and the assumptions used in the calculations.

Beyond comparing patients with controls, the review also examined cancer-related fatigue, one of the most common and difficult symptoms in oncology. Across individual cancer cohorts, studies repeatedly found inverse links between HRV and fatigue severity: lower variability was associated with greater exhaustion. This pattern fits earlier research, including work in breast cancer survivors showing that low HRV can remain tied to persistent fatigue long after treatment has ended. If reduced vagal tone is truly connected to the fatigue experienced by millions of cancer survivors, HRV may eventually help identify people at higher risk and track responses to interventions such as exercise programs, which previous meta-analytic work suggests may partly improve autonomic dysfunction in this group.

The review’s longitudinal studies add another layer. Some followed patients from before surgery through surgery, chemotherapy, and radiation, and then into survivorship, showing that HRV can change across the cancer journey. Vagal withdrawal around surgery, cardiotoxic effects from certain chemotherapy drugs, and the physiological burden of the disease itself may each affect autonomic regulation. Other studies explored whether HRV differs by tumor site or disease progression, and whether nonlinear HRV measures such as fractal and entropy-based indices—known in other populations to predict cardiovascular mortality—might provide prognostic clues in conditions such as brain metastases, gastric cancer, or colorectal cancer. These findings are still preliminary, but they suggest a broader role for autonomic monitoring alongside standard clinical assessment.

At the same time, the authors make clear what the pooled result cannot prove. Because the evidence mixes different possible reasons for lower HRV, including the cancer itself, treatment-related cardiotoxicity, perioperative vagal withdrawal, and long-term changes during survivorship, the overall estimate cannot be attributed to any single cause. The GRADE assessment also rated all pooled outcomes as very low certainty, reflecting weaknesses in study design, possible bias, and limited precision. On that basis, the researchers do not recommend HRV as an established clinical biomarker for cancer care. They emphasize the difference between a consistent research signal and a validated tool for everyday practice.

The next step, according to the authors, is better-designed research that separates patients by treatment phase, uses standardized measurement methods, and includes nonlinear HRV indices alongside the traditional time-domain and frequency-domain measures. Wearable devices, which have already been used in recent observational studies to help classify cancer-related fatigue from HRV signals, could support large-scale monitoring over time outside the clinic. If future work confirms that HRV changes track symptom burden, treatment toxicity, or survival, the millisecond-to-millisecond wobble of the heartbeat could become a practical noninvasive sign in oncology. For now, the review offers cautious confirmation that the autonomic nervous system is measurably altered in cancer, especially in short-term recordings, and that understanding the clinical meaning of this pattern remains an open challenge.

Subject of Research: Heart rate variability suppression in cancer patients versus non-cancer controls: a systematic review and meta-analysis

Article Title: Heart rate variability suppression in cancer patients versus non-cancer controls: a systematic review and meta-analysis

Article References: Heart rate variability suppression in cancer patients versus non-cancer controls: a systematic review and meta-analysis. (n.d.). https://doi.org/10.1007/s00520-026-11229-1

Image Credits: AI Generated

Keywords: Heart, rate, variability, suppression, cancer, patients, versus, non-cancer, controls, systematic, review, meta-analysis